These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. Jambroes M, Weverling GJ, Reiss P, Danner SA, Jurriaans S, ten Veen JH, van der Ende ME, Schutten M, Schneider MM, Schuurman R, Mulder JW, Kroes AC, Lange JM, de Wolf F, Kliniek en Virologie van het ATHENA-project. Ned Tijdschr Geneeskd; 2001 Aug 18; 145(33):1591-7. PubMed ID: 11534377 [Abstract] [Full Text] [Related]
4. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment. Prescrire Int; 2004 Aug 18; 13(72):144-50. PubMed ID: 15532140 [Abstract] [Full Text] [Related]
6. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen AB, Phillips AN, Lundgren JD, EuroSIDA Study Group. J Infect Dis; 2004 Dec 01; 190(11):1947-56. PubMed ID: 15529259 [Abstract] [Full Text] [Related]
8. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V, Red de Investigación en SIDA. J Med Virol; 2005 Sep 01; 77(1):23-8. PubMed ID: 16032728 [Abstract] [Full Text] [Related]
12. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group. Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319 [Abstract] [Full Text] [Related]
13. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients. Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G. Antivir Ther; 2006 Aug 01; 11(2):233-43. PubMed ID: 16640104 [Abstract] [Full Text] [Related]
14. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N. Antivir Ther; 2009 Aug 01; 14(3):339-47. PubMed ID: 19474468 [Abstract] [Full Text] [Related]
15. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. Røge BT, Barfod TS, Kirk O, Katzenstein TL, Obel N, Nielsen H, Pedersen C, Mathiesen LR, Lundgren JD, Gerstoft J. HIV Med; 2004 Sep 01; 5(5):344-51. PubMed ID: 15369509 [Abstract] [Full Text] [Related]
19. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD, EuroSIDA Study Group. AIDS; 2008 Oct 18; 22(16):2187-98. PubMed ID: 18832882 [Abstract] [Full Text] [Related]